<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00631839</url>
  </required_header>
  <id_info>
    <org_study_id>FDCA002</org_study_id>
    <nct_id>NCT00631839</nct_id>
  </id_info>
  <brief_title>Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury</brief_title>
  <official_title>Prospect Study to Evaluate Clinical, Dosimetrical, Functional, Biological and Genetic Factors in Predicting Chemo-Radiotherapy Induced Lung and Esophagus Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Cancer Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Cancer Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate clinical, dosimetrical, functional, biological and&#xD;
      genetic factors in predicting chemo-radiotherapy induced lung and esophagus injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a prospective study to investigate the combinational effect of radiotherapeutic&#xD;
      dosimetric parameters [mean lung dose and percentage of lung volume receiving at least XGy&#xD;
      (Vx)] and biological parameters&#xD;
      [interleukin-1α(IL1α),interleukin-1β(IL1β),interleukin-6(IL6),interleukin-7(IL7),transforming&#xD;
      growth factor beta (TGFB)] and manganese superoxide dismutase(MnSOD) in predicting radiation&#xD;
      pneumonitis, fibrosis, and radiation esophageal injury. Eligibility included pathological or&#xD;
      cytological proven thoracic cancer,ECOG performance status [PS] 0-2, no prior thoracic RT or&#xD;
      chemotherapy,no distant metastasis and signed informed consent prior to study entry.&#xD;
&#xD;
      Basic pre-treatment information will be collected, which included ECOG PS, UICC/AJCC&#xD;
      stage,primary lesion site, history of smoking/coexisting lung disease/surgical resection, and&#xD;
      pulmonary function test of FEV1/VC/DLCO. Computed tomography [CT] of the whole lung in&#xD;
      treatment position. Blood test of IL1α,IL1β,IL6,IL7,TGFB and MnSOD by ELISA will be done&#xD;
      before and weekly during RT. RT must be given by photon energies &gt;=6MV. Radiation lung and&#xD;
      esophageal injury will be assessed according to common toxicity criteria adverse effect&#xD;
      version3.0 [CTCAE-3.0] during RT and in every follow up visits. Genomic DNA is obtained from&#xD;
      the blood drawn during RT. Chi-square test, T test, analysis of variance, logistic&#xD;
      regression, and proportional hazard ratio method will be used to investigate whether the&#xD;
      parameter(s) can be effective in predicting radiation related sequelae.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2002</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chemo-Radiotherapy induced pneumonitis,fibrosis and esophagus injury assessed with common toxicity criteria adverse effect version3.0 [CTCAE-3.0]</measure>
    <time_frame>from the begining of treatment to the end of follow-up</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">140</enrollment>
  <condition>Thoracic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic 3-D Conformal Radiotherapy</intervention_name>
    <description>Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies &gt;=6MV.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Thoracic Radiotherapy(TRT)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients' blood samples will be retained for the purpose of cytokine and MnSOD assay and DNA&#xD;
      detection. The samples will be left till the study ends. Paitents will have their vein blood&#xD;
      drawn from left arm 6am every Monday during RT. All above is stated in informed consent form.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled are Chinese with thoracic neoplasms, no distant metastasis and initially&#xD;
        treated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-pregnant adults (18&lt;= age &lt;= 75 y/o)&#xD;
&#xD;
          -  Chinese ethnicity&#xD;
&#xD;
          -  Pathological or cytological proven thoracic neoplasms (of note,sputum cytology alone&#xD;
             is not acceptable.Cytological specimens obtained by brushing,washing and needle&#xD;
             aspiration of a defined lesion are acceptable)&#xD;
&#xD;
          -  Initially treated&#xD;
&#xD;
          -  No distant metastasis&#xD;
&#xD;
          -  ECOG PS 0-2 (Karnofsky&gt;60%)&#xD;
&#xD;
          -  Understand and willing to sign the consent&#xD;
&#xD;
          -  Normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Leukocytes &gt;=3,000/µL&#xD;
&#xD;
               -  Haemoglobin &gt;=9 g/dL (prior to transfusions)&#xD;
&#xD;
               -  Absolute neutrophil count &gt;=1,500/µL&#xD;
&#xD;
               -  Platelets &gt;=100,000/µL&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x upper limit of normal&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) ≤2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  Creatinine &lt;=2.5 mg/dl.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior thoracic radiotherapy&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Allergic reactions attributed to compounds of similar chemical or biologic composition&#xD;
             to platinum-based drugs.&#xD;
&#xD;
          -  Pre-existed non-oncological pulmonary or esophageal disease that may put the patient&#xD;
             at high risk of severe toxicities.&#xD;
&#xD;
          -  Other uncontrolled intercurrent illness including, but not limited to, ongoing or&#xD;
             active infection and psychiatric illness/social situations that would limit compliance&#xD;
             with study requirement&#xD;
&#xD;
          -  pregnancy or lactating&#xD;
&#xD;
          -  Receiving other investigational agents or devices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Fan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Cancer Hospital, Department of Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University, Cancer Hospital, Department of Radiation Oncology</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>March 2, 2008</study_first_submitted>
  <study_first_submitted_qc>March 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2008</study_first_posted>
  <last_update_submitted>October 6, 2008</last_update_submitted>
  <last_update_submitted_qc>October 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Fan Min, Associate Professor, Vice Chief of Lung Cancer Center, Fudan University</name_title>
    <organization>Shanghai Cancer Hospital, China</organization>
  </responsible_party>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>Platinum-based chemotherapy</keyword>
  <keyword>3-D Conformal Radiotherapy</keyword>
  <keyword>Chemo-radiotherapy induced lung injury</keyword>
  <keyword>Chemo-radiotherapy induced esophagus injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

